跳至主要内容
临床试验/NCT00198484
NCT00198484已完成3 期

Evaluation of Vitrase (Hyaluronidase for Injection) Ovine, 200 USP Units/mL, as an Adjuvant to Increase the Absorption and Dispersion of Other Injected Drugs Prior to Ocular Surgery

Bausch & Lomb Incorporated18 个研究点 分布在 1 个国家目标入组 108 人开始时间: 2004年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
108
试验地点
18
主要终点
Physician Satisfaction Survey

研究概览

简要总结

The purpose of this study is to determine whether Vitrase (hyaluronidase for injection) is effective as a spreading agent for other injected drugs prior to ocular surgery

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Scheduled for an ophthalmic surgical procedure

排除标准

  • Documented history of hypersensitivity to hyaluronidase or any other ingredient in Vitrase
  • Known history of hypersensitivity reaction to bee or wasp venom
  • Needing enhanced absorption and dispersion of dopamine, alpha agonist drugs, furosemide, the benzodiazepines, or phenytoin
  • Inflammation or apparent clinical signs of infection in the area where Vitrase was to be injected

研究组 & 干预措施

Vitrase

Experimental

ovine hyaluronidase injection 150 USP Units in 1 mL solution. Single dose of Vitrase will be administered as an adjuvant prior to ophthalmologic surgery

干预措施: Vitrase (Drug)

结局指标

主要结局

Physician Satisfaction Survey

时间窗: 1-2 days

Physician evaluation of effectiveness of Vitrase as an adjuvant and overall satisfaction, via questionnaire;

次要结局

  • Adverse Events(1-2 days)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (18)

Loading locations...

相似试验